Genscript Biotech Past Earnings Performance
Past criteria checks 0/6
Genscript Biotech's earnings have been declining at an average annual rate of -23.2%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 25.7% per year.
Key information
-23.2%
Earnings growth rate
-21.2%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 25.7% |
| Return on equity | -17.4% |
| Net Margin | -11.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Genscript Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 840 | -95 | 393 | 433 |
| 30 Sep 23 | 773 | -140 | 383 | 426 |
| 30 Jun 23 | 707 | -185 | 374 | 420 |
| 31 Mar 23 | 667 | -206 | 363 | 405 |
| 31 Dec 22 | 626 | -227 | 352 | 390 |
| 30 Sep 22 | 598 | -315 | 354 | 375 |
| 30 Jun 22 | 570 | -403 | 356 | 361 |
| 31 Mar 22 | 530 | -381 | 330 | 360 |
| 31 Dec 21 | 490 | -359 | 303 | 358 |
| 30 Sep 21 | 483 | -265 | 270 | 341 |
| 30 Jun 21 | 454 | -183 | 235 | 323 |
| 31 Mar 21 | 422 | -194 | 216 | 293 |
| 31 Dec 20 | 391 | -205 | 197 | 263 |
| 30 Sep 20 | 354 | -194 | 171 | 251 |
| 30 Jun 20 | 318 | -183 | 146 | 239 |
| 31 Mar 20 | 296 | -140 | 136 | 212 |
| 31 Dec 19 | 273 | -97 | 126 | 186 |
| 30 Sep 19 | 257 | -59 | 112 | 148 |
| 30 Jun 19 | 241 | -22 | 98 | 109 |
| 31 Mar 19 | 236 | 0 | 89 | 92 |
| 31 Dec 18 | 231 | 21 | 79 | 74 |
| 30 Sep 18 | 216 | 24 | 72 | 58 |
| 30 Jun 18 | 201 | 27 | 65 | 41 |
| 31 Mar 18 | 177 | 26 | 56 | 30 |
| 31 Dec 17 | 153 | 26 | 47 | 18 |
| 30 Sep 17 | 139 | 27 | 48 | 11 |
| 30 Jun 17 | 125 | 28 | 49 | 5 |
| 31 Mar 17 | 120 | 27 | 50 | 2 |
| 31 Dec 16 | 115 | 26 | 51 | 0 |
| 30 Sep 16 | 107 | 26 | 50 | 0 |
| 30 Jun 16 | 99 | 25 | 48 | 0 |
| 31 Mar 16 | 93 | 21 | 47 | 0 |
| 31 Dec 15 | 87 | 18 | 46 | 0 |
| 30 Sep 15 | 82 | 13 | 43 | 0 |
| 30 Jun 15 | 78 | 8 | 39 | 0 |
| 31 Mar 15 | 74 | 7 | 38 | 0 |
| 31 Dec 14 | 70 | 6 | 37 | 0 |
| 31 Dec 13 | 60 | 6 | 29 | 0 |
Quality Earnings: G51 is currently unprofitable.
Growing Profit Margin: G51 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: G51 is unprofitable, and losses have increased over the past 5 years at a rate of 23.2% per year.
Accelerating Growth: Unable to compare G51's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: G51 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Return on Equity
High ROE: G51 has a negative Return on Equity (-17.37%), as it is currently unprofitable.